Joseph Jacob, Loscalzo Joseph
Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA,
Curr Atheroscler Rep. 2015 May;17(5):505. doi: 10.1007/s11883-015-0505-x.
In addition to the interaction of nutrition and genetic variation on the genesis and natural history of cardiovascular disease, recent studies have revealed an entire new genome that resides in the trillions of microbes that exist in various human habitats, predominantly in the gut, that may also contribute to the pathogenesis of cardiovascular disease. This microbial genome and the proteins for which it codes have important functions in homeostatic adaptations to the past and present changes in diet and environment accompanying human civilization. Both preclinical and clinical investigations suggest the role of commensal microbiota in promoting adverse cardiovascular risk. Specifically, microbial metabolism of methylated amines leads to direct pro-atherogenic effects in humans. Further investigations are needed to understand the complex relationships among nutritional status, genetic variation, and the microbial genome, which may explain the recent negative results of clinical trials of nutritional interventions such as B vitamin therapy to lower plasma homocysteine levels. The results of such contemporary genomic investigations would allow us to utilize personalized nutritional interventions to reduce cardiovascular risk.
除了营养与基因变异在心血管疾病发生及自然史中的相互作用外,最近的研究还揭示了一个全新的基因组,它存在于人类各种栖息地(主要是肠道)中的数万亿微生物中,这也可能导致心血管疾病的发病机制。这种微生物基因组及其编码的蛋白质在对伴随人类文明而来的过去和现在饮食及环境变化的稳态适应中具有重要功能。临床前和临床研究均表明共生微生物群在促进不良心血管风险方面的作用。具体而言,甲基化胺的微生物代谢会对人类产生直接的促动脉粥样硬化作用。需要进一步研究以了解营养状况、基因变异和微生物基因组之间的复杂关系,这可能解释了诸如B族维生素疗法降低血浆同型半胱氨酸水平等营养干预临床试验最近出现的负面结果。此类当代基因组研究的结果将使我们能够利用个性化营养干预措施来降低心血管风险。